New study explores how genetic risk info shapes ovarian cancer decisions
NCT ID NCT06436248
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 38 times
Summary
This study interviews 24 women with BRCA1 or BRCA2 mutations to learn how they might use polygenic risk scores and multi-cancer early detection tests when deciding about cancer screening or risk-reducing surgery. The goal is to better understand patient attitudes, not to test a treatment. Results could help doctors support informed decision-making.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Abramson Cancer Center
Philadelphia, Pennsylvania, 19104, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.